Hepalink

Executive Summary

Shenzhen Hepalink Pharmaceutical Group is a leading multinational biopharmaceutical company with a vertically integrated heparin industrial chain, a growing CDMO business for large molecule biologics and gene therapy, and an innovative drug pipeline targeting cardiovascular and biologic therapeutics. Founded in 1998 and headquartered in Shenzhen, China, Hepalink has evolved from a heparin raw material supplier into a global player with commercial-stage products and over 1,000 employees. The company's heparin franchise benefits from strong demand for anticoagulants, while its CDMO segment capitalizes on the expansion of biologic and gene therapy manufacturing. Hepalink's innovative pipeline includes several preclinical and clinical stage assets, though details remain limited. The company's public listing provides transparency, but geopolitical risks and reliance on the Chinese regulatory environment are notable challenges. Overall, Hepalink is positioned for steady growth driven by its integrated heparin business and CDMO expansion, with potential upside from pipeline progress.

Upcoming Catalysts (preview)

• Q3 2026FDA or EMA decision on new heparin product or indication50% success
• Q4 2026Major CDMO contract win for biologic or gene therapy manufacturing40% success
• Q1 2027Clinical data readout from pipeline candidate (e.g., cardiovascular drug)35% success